Nicotine vaping product use, harm perception and policy support among pharmacy customers in Brisbane, Australia by Erku, Daniel A. et al.
1 
 
Erku et al. 2019. Drug and Alcohol Review 38: 703-711 1 
Doi: https://doi.org/10.1111/dar.12984  2 
 3 
Nicotine vaping product use, harm perception and policy support among pharmacy 4 
customers in Brisbane, Australia 5 
Daniel A Erku1*, Coral E Gartner2, 3, Unchanok Tengphakwaen1, Kylie Morphett2, and Kathryn 6 
J Steadman1 7 
1School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba 8 
4102, Queensland, Australia 9 
2School of Public Health, The University of Queensland, Herston Road, Herston 4006, 10 
Queensland, Australia 11 
3Queensland Alliance for Environmental Health Sciences, The University of Queensland, 20 12 
Cornwall Street, Woolloongabba 4102, Queensland, Australia 13 
Email addresses: 14 
Daniel A Erku: d.erku@uq.edu.au  15 
Coral Gartner: c.gartner@uq.edu.au  16 
Unchanok Tengphakwaen: unchanok.tengphakwaen@uq.net.au  17 
Kylie Morphett: k.morphett@uq.edu.au  18 
Kathryn Steadman: k.steadman@uq.edu.au   19 
 20 
[Short running title: Pharmacy customers’ use and opinion on vaping] 21 
 22 
*Corresponding author 23 
Postal address: School of Pharmacy, The University of Queensland, Pharmacy Australia Centre 24 
of Excellence, 20 Cornwall Street, Woolloongabba QLD 4102, Australia 25 
2 
 
Abstract  26 
Introduction and Aims. Despite regulatory barriers for accessing nicotine liquid, use of 27 
nicotine vaping products (NVPs) has increased rapidly in Australia. Legal use of NVPs to aid 28 
smoking cessation requires a prescription, and pharmacies report receiving enquiries about the 29 
use of and access to NVPs. In this study, we assessed NVPs use, harm perception and policy 30 
support among community pharmacy customers. 31 
Design and Methods. A cross-sectional survey was conducted among customers (n=470) from 32 
a large community pharmacy chain in Brisbane, Australia. Multivariable logistic regression 33 
was used to examine perception of NVPs as less harmful than combustible cigarettes and 34 
regulatory recommendations in relation to demographics, smoking status and NVP use.  35 
Results. Almost one-third of the sample (31%) had either tried NVPs in the past (16%) or were 36 
current vapers (15%), the majority of them being current smokers (67%) who are trying to quit 37 
(31%) or substitute smoking (41%). Vapers primarily depended on family/friends as a source 38 
of information (76%). Current smokers and vapers were more likely to perceive NVPs as less 39 
harmful than cigarettes than non-smokers and non-vapers. Perceiving NVPs as safer than 40 
cigarettes was correlated with a recommendation to regulate as a tobacco product. 41 
Discussion and Conclusions. There was widespread misperception about relative risk of 42 
nicotine-containing products, with 37% of respondents perceiving nicotine-containing NVPs 43 
to be as harmful as combustible cigarettes. Community pharmacies represent an ideal setting 44 
for educating smokers about smoking and vaping. Thus, pharmacy staff need educational 45 
support to ensure that they are equipped to provide current evidence-based information to 46 
customers.  47 
Key words: E-cigarette, Harm perception, Vaping, Australia 48 
 49 
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Introduction  54 
Nicotine vaping products (NVPs), also known as electronic nicotine delivery systems 55 
(exemplified by electronic cigarettes or e-cigarettes), are a group of products that deliver 56 
nicotine in the form of an aerosol (1). There has been a rapid increase in NVP use globally 57 
since their first introduction into the market in mid 2000s (2). Acceptance and patterns of use 58 
vary considerably across countries with rapid uptake evident in countries that have more liberal 59 
regulations concerning the use and marketing of these products (3, 4). For instance, these 60 
products are now more popular than nicotine replacement therapies (NRTs) for smoking 61 
cessation in the UK, where they are widely available as consumer products (5). 62 
In Australia, the laws regulating NVPs are complex and vary between jurisdictions. In all states 63 
and territories, apart from Western Australia, vaping devices without nicotine can be sold as 64 
consumer products. Over the past five years, most Australian states and territories have 65 
introduced further regulations on the sale and use of nicotine-free vaping products similar to 66 
regulations that are applied to combustible cigarettes. However, it is illegal to use nicotine 67 
(classified as a dangerous poison or Schedule 7) in vaping products unless for a therapeutic 68 
purpose such as quitting smoking, in which case nicotine delivered by lung inhalation is 69 
classified as a prescription-only medicine (Schedule 4) and the user must hold a valid medical 70 
prescription written by a registered medical practitioner. The Therapeutic Goods 71 
Administration (TGA) has indicated that it is possible for a nicotine-containing NVP to be 72 
approved as an aid to quit smoking (6), but as no product has progressed through the regulatory 73 
system there is currently no commercial product available to be prescribed. So, currently 74 
Australians can only access nicotine for use in NVPs using one of the legal pathways for 75 
accessing unapproved therapeutic goods: personal importation, the Special Access Scheme, 76 
Authorised Prescriber Scheme and extemporaneous compounding (7). Despite this regulatory 77 
barrier, use of NVPs among Australian smokers significantly increased between 2013 and 2016 78 
(8). In 2016, approximately one third of smokers in Australia (31%) had tried vaping and 4.4% 79 
reported currently vaping (8). It is unclear what proportion of those respondents vape with 80 
nicotine, but in a separate study conducted in 2016, 91% of NVP users in Australia reported 81 
that their devices contained nicotine (9). The public’s understanding of the regulations, and 82 
their beliefs on what future regulatory frameworks should look like, could inform regulatory 83 
efforts and implementation of new NVP-related policies. Assessing risk perceptions and policy 84 
opinions of smokers, particularly those who have difficulty quitting smoking, are valuable 85 
since they are the population who may benefit from using NVPs to quit smoking. The views of 86 
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non-smokers are also relevant because of concerns about non-smoking youth accessing NVPs 87 
and potentially becoming addicted to nicotine. 88 
Understanding perceptions of individuals about the relative safety of a particular behaviour 89 
provides a basis for a predictive relationship between perception and engagement in such 90 
behaviours. For instance, there appears to be a direct relationship between smokers’ perception 91 
of the relative harm of tobacco cigarettes and NVPs and the likelihood of switching from 92 
smoking to vaping (10, 11). A longitudinal study showed that smokers/ex-smokers who 93 
perceived NVPs as less harmful than smoking were more likely to subsequently try them (10). 94 
In the majority of studies that assessed perceptions regarding the continuum of risk across 95 
nicotine products, NVPs, hookah and smokeless tobacco products were perceived as less 96 
harmful compared to combustible cigarettes (12). However, a considerable proportion of 97 
smokers also report lack of knowledge about the relative safety (13), or believe NVPs are 98 
equally harmful to tobacco cigarettes (13, 14). Similar misperceptions have also been reported 99 
for nicotine in general, with a belief that nicotine is responsible for most smoking-related death 100 
and disease (14, 15). Such lack of knowledge or misperception regarding relative harm could 101 
potentially impede switching from smoking to lower-risk alternative products such as NVPs.  102 
In a study conducted to evaluate the effect of recruitment setting on the composition of samples 103 
consisting of adult smokers, community pharmacy settings were found to be better than general 104 
practice sites in terms of recruiting hard-to-quit smokers and those who are pre-contemplators 105 
of smoking cessation (16). This conclusion led the authors to suggest that community 106 
pharmacies, being situated at the interface between primary health care and the general public, 107 
represent an ideal recruitment site for targeting smokers who are either unwilling or less likely 108 
to succeed at quitting. In addition, community pharmacies are an ideal setting for brief 109 
interventions (e.g. providing smoking cessation counselling in the form of ask, advise and refer 110 
approach) particularly to underserved and priority populations (17). Pharmacy staff represent 111 
a highly accessible trained workforce and are uniquely positioned to provide evidence-based 112 
information about the relative risks of various nicotine-containing products to smokers(18). A 113 
recent study conducted in Australia found that pharmacy staff are frequently asked about NVPs 114 
by their customers, but reported feeling uninformed about these products and indicated the 115 
need for more information and guidance about NVPs (19). Exploring customers’ level of 116 
knowledge, harm perceptions and motivations for use of NVPs could, therefore, inform the 117 
development of practice guidelines for pharmacy staff that will ultimately assist in providing a 118 
customised, evidence-based and unbiased information to their customers. In this study, we 119 
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assessed pharmacy customer use of NVPs, reason/motivation for use, and source of 120 
information as well as perceived beliefs regarding the relative risk of various nicotine-121 
containing products (i.e. smokeless tobacco products, NRTs, NVPs and combustible tobacco 122 
cigarettes). We also asked respondents to indicate their views regarding how the sale of NVPs 123 
(with and without nicotine) should be regulated in Australia.  124 
Methods 125 
A cross-sectional survey of pharmacy customers was conducted. All adult pharmacy customers 126 
who visited four pharmacies of a large private pharmacy chain in various suburbs of Brisbane, 127 
Queensland, Australia, during a one-week period in March 2015 for each pharmacy, were 128 
approached and invited to participate. These were a convenience sample selected to access a 129 
range of pharmacy customers (two based in the city and two in suburban areas). Human 130 
Research Ethics approval was granted by the University of Queensland, School of Pharmacy 131 
Ethics Committee. Participants were provided with an information sheet explaining the aim of 132 
the survey and consent to participate was confirmed verbally prior to data collection. 133 
Participants were given the option to complete the survey via a face-to-face interview or to 134 
complete the questionnaire themselves in the presence of the data collector. Participation was 135 
voluntary and no incentive was provided. 136 
No suitable validated tool was identified, so the questionnaire was developed based on other 137 
surveys conducted by our collaborators about consumer views and preferences of lower-risk 138 
alternatives to smoking including NVPs (20-22). The questionnaire was piloted for 139 
comprehensibility with five members of the general public recruited through the research 140 
team’s social networks, and slight adjustments made accordingly. The final questionnaire 141 
included three sections. Section one contained questions on demographic characteristics of the 142 
participants including age, gender, educational status, ever use of combustible cigarettes and 143 
quit attempts. Among smokers who had previously made a quit attempt, a follow up item 144 
queried the type of smoking cessation methods used/tried. Respondents were also asked 145 
whether they had ever tried and/or were currently vaping, and asked to specify whether they 146 
used nicotine or non-nicotine NVPs. All respondents who had ever used and/or were currently 147 
using NVPs were asked about their reasons for using them with the following possible answers, 148 
selecting all that apply from the following list: to quit smoking; to cut down the number of 149 
tobacco cigarettes I smoke; as a substitute for smoking tobacco; because it does not have 150 
smoke; because it is safer than smoking tobacco; to use in areas where smoking is banned; my 151 
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friends or family members recommended them; my health professional (Pharmacist, Doctor, 152 
Counsellor etc.) recommended them; I like the taste; and to save money.  153 
Section two assessed the perceived beliefs of respondents regarding the relative risk of various 154 
nicotine-containing products including smokeless tobacco products, NRTs, NVPs compared to 155 
combustible tobacco cigarettes with the question, “How harmful are the following 156 
items/products, compared to regular tobacco cigarettes?” Responses were measured on a 5-157 
point Likert scale ranging from “Much less harmful” to “Much more harmful”. Perception 158 
regarding short and long term safety of nicotine-containing NVPs were also assessed by the 159 
questions “Nicotine-containing e-cigarettes are safe to use for (1) short term (<6 months); (2) 160 
long term (>6 months or lifetime)” and “Nicotine-containing e-cigarettes are safer than NRTs”. 161 
Responses were measured on a 5-point Likert scale ranging from “Strongly disagree to 162 
“Strongly agree”.  163 
Finally, respondents were asked to indicate their views on whether the sale of NVPs (with or 164 
without nicotine) should be regulated in Queensland as consumer, tobacco, or medicinal 165 
products, with the following options: 1) Should be sold on the shelf in general retail outlets; 2) 166 
Should be sold under the counter to adults, like tobacco; 3) Should only be sold in pharmacies 167 
with advice from a pharmacist; 4) should require a prescription from a doctor; and 5) should 168 
be illegal to sell.  169 
Data analysis 170 
The data were entered into and analysed using IBM SPSS Statistics 24.0 (SPSS Inc., Chicago, 171 
IL, USA). Descriptive statistics (frequencies and percentages) were employed to summarise 172 
demographic and smoking characteristics of participants, stratified as ‘never’, ‘former’ or 173 
‘current’ NVP users. Descriptive statistics were also used to explore respondents’ views on the 174 
sale of NVPs, stratified by smoking status (‘current’, ‘former’, and ‘non-smoker’). Bivariate 175 
analysis and multivariable logistic regression analysis were employed to determine factors 176 
associated with (1) perceiving NVPs as less harmful than combustible cigarettes (vs equally or 177 
more harmful) and (2) regulatory recommendations (a consumer product, a tobacco product, 178 
medicinal product or complete ban) were examined using multivariable logistic regressions. 179 
The results were adjusted for demographics characteristics, smoking status and NVP use. Odds 180 
ratio (OR) with 95% confidence interval (95% CI) were also computed along with 181 
corresponding p-value; p < 0.05 was taken as indicating statistical significance. 182 
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Results 183 
Demographic and smoking characteristics 184 
A total of 744 pharmacy customers were invited to participate, of which 470 respondents 185 
consented and completed the questionnaire giving a response rate of 63.2%. The socio-186 
demographic characteristics of respondents are described in Table 1. The sample consisted of 187 
approximately equal proportion of men (52%) and women (48%), nearly half (47%) had a 188 
tertiary level qualification and a small proportion identified as Aboriginal and/or Torres Strait 189 
Islander (12%). Over half of the respondents (53.6%) were either current smokers (31.5%) or 190 
ex-smokers (22.1%). Among current smokers, 112 (76%) indicated having tried to quit 191 
smoking at least once, with the most common methods being ‘cold turkey’ (91%), NRTs (64%) 192 
and NVPs (51%).  193 
 194 
Use of NVPs 195 
Almost a third of the respondents (30.8%) had either tried NVPs in the past (15.9%) or were 196 
current users (14.8%). The majority of vapers (former and current) were male (70.3%, OR 4.64, 197 
95% CI: 2.22-10.10, p=<0.001) and current smokers (66.7%, OR 79.3, 95% CI: 25.39-247.1, 198 
p=<0.001). Of the 70 people that reported being current NVP users, all except one of them 199 
were current or former smokers (Table 1). The most commonly mentioned reasons for NVP 200 
use were ‘as a substitute for smoking tobacco’ (41.4%), ‘it is safer than smoking tobacco’ 201 
(40%), ‘to quit smoking’ (31%) and ‘to cut down the number of cigarettes I smoke’ (26.2%). 202 
The majority of vapers reported that family/friends (75.9%) had recommended they try NVPs, 203 
with only two (1.4%) users reporting being advised to try them by a healthcare professional. 204 
Perceived safety of NVPs 205 
Over half of respondents (56%) agreed or strongly agreed that short-term use (less than 6 206 
months) of NVPs is safe. However, respondents were wary of long-term or lifetime use of 207 
NVPs; more respondents disagreed (62%) than agreed (18%) with the statement that lifetime 208 
use of NVP is safe (Figure 1).  209 
The majority of respondents believed that NVPs with nicotine (61.5%) or without nicotine 210 
(83.2%) are less harmful than combustible cigarettes (Table 2). When stratifying harm 211 
perception according to NVP use, the difference in harm perception among current, former and 212 
never vapers is apparent. Current vapers perceived NVPs as less harmful than combustible 213 
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cigarettes, irrespective of whether they contained nicotine (93%) or were nicotine-free (97%). 214 
In contrast, nearly half of non-users (46.5%) perceived nicotine-containing NVPs to be equally 215 
as harmful as smoking, however this dropped to 20% for NVPs without nicotine. The majority 216 
of respondents disagreed (60%) and few agreed (12%) with the statement that NVPs are safer 217 
than NRTs. Nearly all respondents who disagreed (255 out of 282 respondents) did not use 218 
NVPs, with only 3 current vapers disagreeing with the statement.   219 
 220 
Figure 1. Respondents’ opinions about the safety of e-cigarettes containing nicotine, n=470 221 
 222 
  223 
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Table 1. Demographic and smoking characteristics of participants, stratified by NVP use, 224 
n=470 225 
Variables NVP use, n (%) Total n (%) 
Never Former Current 
Gender  
Male  142 (30.2) 51 (10.8) 51 (10.8) 244  (51.9) 
Female  183 (38.9) 24 (5.1) 19 (4.0) 226 (48.1) 
Age          
18-25  40 (8.5) 16 (3.4) 33 (7.0) 89 (18.9) 
26-35 86 (18.3) 35 (7.4) 27 (5.7) 148 (31.5) 
36-45 63 (13.4) 14 (3.0) 8 (1.7) 85 (18.1) 
≥46 136 (29.9) 10 (2.0) 2 (0.4) 148 (31.5) 
Educational level         
Less than year 12 14 (3.0) 6 (1.3) 2 (0.4) 22 (4.7) 
Senior school certificate 79 (16.8) 29 (61.7) 18 (3.8) 126 (26.8) 
Post-school qualification 67 (14.2) 17 (3.6) 17 (3.6) 101 (21.5) 
University level 165 (35.1) 23 (4.9) 33 (7.0) 221 (47) 
Ethnicity (n=458)         
Australian 192 (58.5) 29 (39.7) 21 (30.4) 242 (51.5) 
Aboriginal or Torres Strait 
 
27 (8.2) 26 (35.6) 14 (20.3) 57 (12.1) 
European  37 (11.3) 8 (10.9) 12 (17.4) 57 (12.1) 
East Asian 42 (12.8) 8 (11) 15 (21.7) 65 (13.8) 
Other*  30  (9.0) 2  (2.7) 7  (10.1) 37  (7.8) 
Smoking status         
Current 43 (9) 54 (11.4) 51 (10.8) 148 (31.5) 
Former 69 (14.7) 17 (3.6) 18 (3.8) 104 (22.1) 
Never 213 (45.3) 4 (0.8) 1 (0.2) 218 (46.4) 
*Other: the Americas, Southern & Central Asian and African descent  226 
 227 
  228 
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Table 2. Perceived safety of various nicotine-containing products compared to combustible 229 
cigarettes, n=470 230 
Relative safety compared 
to tobacco cigarettes* 
NVP use status Total 
Current, n (%) Former, n (%) Never, n (%)   
Nicotine replacement therapies  
Less harmful 68 (97.1) 71 (94.7) 318 (97.8) 457 (97.2) 
Equally harmful  2 (2.9) 4 (5.3) 7 (2.2) 13 (2.8) 
More harmful  0  0  0  0  
E-cigarettes with nicotine  
Less harmful 65 (92.8) 56 (74.7) 168 (51.7) 289 (61.5) 
Equally harmful  5 (7.2) 18 (24) 151 (46.5) 174 (37) 
More harmful  0  1 (1.3) 6 (1.8) 7 (1.5) 
E-cigarettes without nicotine 
Less harmful 68 (97.1) 67 (89.3) 256 (78.8) 391 (83.2) 
Equally harmful  2 (2.9) 8 (10.7) 65 (20) 75 (16) 
More harmful  0  0  4 (2.2) 4 (0.8) 
Herbal cigarettes   
Less harmful     28 (40) 35 (46.7) 161 (49.5) 224 (47.6) 
Equally harmful  41 (58.6) 37 (49.3) 155 (47.7) 233 (49.6) 
More harmful  1 (1.4) 3 (4.0) 9 (2.8) 13 (2.8) 
Smokeless tobacco products   
Less harmful 33 (47.1) 36 (48) 127 (39.1) 196 (41.7) 
Equally harmful  28 (40) 31 (41.3) 137 (42.1) 196 (41.7) 
More harmful  9 (12.9) 8 (10.7) 61 (18.8) 78 (16.6) 
*responses for ‘less harmful’ and ‘much less harmful’ were combined and presented as 231 
‘less/more harmful’. Responses for ‘more harmful’ and ‘much more harmful’ were combined 232 
and presented as ‘more harmful’. 233 
 234 
In the adjusted logistic regression model (Table 3), age, use of NVPs and smoking status were 235 
strongly correlated with accurately perceiving NVPs as less harmful compared to traditional 236 
cigarettes. Respondents in the age range of 18-25 years were 4.62 times more likely to perceive 237 
NVPs as less harmful compared to combustible cigarettes than those greater than 45 years old 238 
(OR 4.62, 95% CI: 2.30-9.26, p=< 0.001). Current smokers (OR 2.61, 95% CI: 1.39-4.92, 239 
p=<0.002) and NVPs users (OR 3.89, 95% CI: 1.37-11.06, p=< 0.010) were also more likely 240 
to perceive NVPs as less harmful compared to combustible cigarettes than non-smokers and 241 
NVP non-users. 242 
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Table 3. Logistic regression analyses of the perception that NVPs are less harmful than 243 
combustible cigarettes (vs equally/more harmful), adjusted for age range, smoking status and 244 
NVP use, n=470 245 
Variables  β S.E. Odds 
ratio 
95% CI p-value 
Lower Upper  
Age range (ref: ≥46)      < 0.001 
18-25 1.53 0.35 4.62 2.30 9.26 < 0.001 
26-35 1.19 0.27 3.29 1.92 5.68 < 0.001 
36-45 0.59 0.88 1.81 1.03 3.18 0.039 
Smoking status (ref: non-smokers) 0.011 
Current smokers 0.96 0.32 2.61 1.39 4.92 0.002 
Former smokers 0.41 0.28 1.52 0.87 2.64 0.137 
NVP use (ref: non-user)  0.035 
Current users 1.36 0.53 3.89 1.37 11.06 0.010 
Former users -1.32 0.79 0.27 0.06 1.26 0.095 
Model summary: Chi-square: 99.13 (p=< 0.001); Cox & Snell R Square (0.190); Nagelkerke 246 
R Square (0.258); Hosmer and Lemeshow Test (9.12; P=0.332) 247 
 248 
Opinion regarding regulation of NVPs 249 
The majority of non-smokers supported regulating nicotine-containing NVPs either as a 250 
medicinal product (45%) or completely banning them (42.2%). They also believed that NVPs 251 
without nicotine should be treated the same as tobacco (38.1%) and only sold ‘under the 252 
counter’, which involves products being shielded from view of the general public with sale to 253 
over 18s only. Alternatively, a third (33.5%) viewed regulation as a medicinal product to be 254 
appropriate. On the other hand, the majority of current smokers recommended regulating both 255 
NVPs with (66.2%) and without nicotine (73.6%) as tobacco products, with only a minority of 256 
them recommending a medicinal route (22.3% for nicotine-containing and 6.8% for NVPs 257 
without nicotine) (Table 4). In the logistic regression model, perceiving nicotine-containing 258 
NVPs as safer than combustible cigarettes (vs equally or more harmful) was correlated with 259 
the recommendation to regulate them as tobacco products (OR 4.61, 95% CI: 1.65-12.84, p= 260 
0.03). 261 
 262 
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 263 
Table 4. Opinions regarding the sale of nicotine and non-nicotine NVPs in Queensland, 264 
(n=470). 265 
Regulation of NVPs Smoker Status, N (%) 
Current Former smoker Non-smoker 
How do you think e-cigarettes containing nicotine should be regulated? 
As consumer products 12 (8.1) 16 (15.4) 1 (0.4) 
As tobacco products 98 (62.2) 25 (24) 27 (12.4) 
As medicinal  products* 33 (22.3) 30 (28.8) 98 (45) 
Should be illegal to sell 5 (3.3) 33 (31.7) 92 (42.2) 
How do you think e-cigarettes without nicotine should be regulated? 
As consumer products 26 (17.6) 23 (22.1) 8 (3.7) 
As tobacco products 109 (73.6) 38 (36.5) 83 (38.1) 
As medicinal  products* 10 (6.7) 25 (24) 73 (34.5) 
Should be illegal to sell 3 (2.1) 18 (17.4) 54 (24.8) 
*pharmacy only or prescription only 266 
 267 
Discussion  268 
In this study, we surveyed adult pharmacy customers about their use and harm perceptions 269 
about NVPs, and opinions on their regulation. Approximately one-third of the sample had 270 
either tried NVPs in the past or were current vapers, the majority of them being current smokers 271 
who are trying to quit smoking. Although pharmacy customers did not believe vaping to be 272 
more harmful than smoking combustible cigarettes, many respondents (37%) perceived 273 
nicotine-containing NVPs to be as harmful as combustible cigarettes. This misperception about 274 
relative risk of various nicotine-containing products was also reflected in respondent regulatory 275 
recommendations as they tended to prefer a more restrictive regulatory approach for NVPs 276 
containing nicotine, supporting a complete ban or regulation as a medicinal product.  277 
In Australia, the number of smokers who have tried NVPs has significantly increased in recent 278 
years. While only 1.2% of adults reported currently using NVPs in the 2016 National Drug 279 
Strategy Household Survey, nearly a third of smokers (31%) reported having ever having tried 280 
NVPs (23). NVP users (current or former) in our study perceived them as safer than smoked 281 
tobacco and had or were using them for the purpose of quitting, substituting or reducing the 282 
number of cigarettes smoked. Similar published studies also found male gender and being a 283 
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smoker (ex- or current) as factors associated with NVP use (24-26). While ever use of NVPs 284 
in our sample was higher (31%) than an online survey of 1,001 adults conducted in New South 285 
Wales (13%), both studies identified males and current smokers as mostly likely to be NVP 286 
users, and smoking cessation as the most common reason for using NVPs (27). Similar 287 
perceived advantages of NVP use were also reported in other studies (24, 28-30). 288 
Over two-thirds of respondents believed that NVPs are less harmful than combustible 289 
cigarettes. In the multivariable logistic regression analysis, respondents in the age range of 18-290 
25 years, current smokers and NVP users were more likely to perceive NVPs as less harmful 291 
than combusted tobacco. Stratifying harm perception according to NVP use generated an 292 
interesting finding. Current vapers perceived NVPs as less harmful than combustible cigarettes, 293 
irrespective of whether they contained nicotine or not. In contrast, the majority of non-users 294 
considered NVPs as less harmful than cigarettes if they were nicotine-free, but fewer non-users 295 
believed this for NVPs containing nicotine. Even though we did not specifically ask the 296 
respondents for their views on nicotine, these findings indicate a potential misperception 297 
among people who have never tried NVPs that nicotine is an important source of any harm 298 
from using NVPs. Indeed, studies conducted across the globe have reported that many believe 299 
NVPs to be less harmful than combustible cigarettes, yet a significant proportion have concerns 300 
and misperceptions regarding nicotine (10, 13, 15, 31). Nicotine is a highly addictive substance, 301 
but it is the mixture of more than 4,000 chemicals (tar) that is produced as a result of the 302 
combustion that kills nearly half of long term smokers (32). While the majority of respondents 303 
believed that short term use of NVPs is safe, they become wary when asked about safety of 304 
long term use of NVPs and relative safety compared to NRTs. Due to being relatively new 305 
products, safety of long term use of NVPs is currently not known. Findings from various 306 
toxicological and short-term human studies, however, suggest that completely switching from 307 
smoking to vaping reduces short term adverse health outcomes (33). 308 
Generally, Australia follows a highly restrictive regulatory approach to NVPs.  Few Australian 309 
health and medical organisations have endorsed them as a cessation aid or harm reduction tool 310 
for smokers. Rather, policy briefings, media releases and position statements from notable 311 
health bodies focus mainly on the potential dangers associated with NVPs (34) unlike some 312 
other western countries (35). This portrayal of NVPs as dangerous products could have an 313 
impact on attitudes held by smokers and the general public towards their safety and what is an 314 
appropriate regulatory approach. The majority of non-smokers in our study supported a 315 
complete ban or a medicinal route for NVPs containing nicotine while allowing NVPs without 316 
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nicotine to be sold as tobacco products, mirroring current Australian regulations (36). Most 317 
jurisdictions in Australia (except Western Australia) allow NVPs without nicotine to be legally 318 
sold and used in places where smoking is allowed. However, since nicotine is classified as a 319 
‘dangerous poison’ when not in human therapeutic or veterinary products (37), it is illegal to 320 
use NVPs containing nicotine unless the person holds a valid medical prescription (7). Such a 321 
regulatory approach is difficult to monitor and enforce owing to the difficulty of differentiating 322 
nicotine-containing from nicotine-free solutions. It is also difficult to regulate product quality 323 
under the current legislation. For instance, a recent study reported that e-liquids sold in 324 
Australia as 'nicotine-free' actually contained nicotine (38), albeit at low levels, and most 325 
Australian vapers rely on overseas online sources for nicotine-containing e-liquids (39). 326 
A significant proportion of current smokers supported a regulatory environment that would 327 
allow NVPs (with or without nicotine) to be regulated in the same way as tobacco products. 328 
This regulatory option was also preferred by respondents who perceived NVPs as safer than 329 
combustible cigarettes. In a similar study conducted among US smokers and non-smokers, it 330 
was reported that perceived beliefs in the relative safety of NVPs was directly correlated with 331 
their regulatory preference, such that respondents who believe NVPs are harmful will more 332 
likely support policies that minimize use (40). Studies also reported that NVP users, 333 
respondents having accurate knowledge about nicotine, and those who perceived NVPs as less 334 
harmful than tobacco cigarettes were more likely to support a less restrictive regulatory 335 
approach (41).  336 
The majority of vapers in our study reported receiving information about NVPs from their 337 
family/friends whereas only 1.4% of users had been advised by a HCP to use NVPs. Previous 338 
studies conducted in the US have reported that most adults learnt about NVPs either through a 339 
personal contact (a friend or family member), seeing them displayed in retail outlets (42) or 340 
from the internet and social media (43). However, information sourced from the media and/or 341 
anecdotal experiences may be biased and could lead to confusion as the content may not be 342 
scientifically valid. The finding that few participants had received advice from a healthcare 343 
professional about NVPs corroborates findings from a recent systematic review, which found 344 
healthcare professionals do not engage in routine communication with patients regarding NVPs 345 
and other low risk alternatives to smoking (18). Due to their geographic distribution and ease 346 
of accessibility, community pharmacies represent an ideal setting to educate the public and 347 
promote behaviours that improve health, one of which is smoking cessation. More than one-348 
third of staff (39%) in community pharmacies in Brisbane, Australia report being asked about 349 
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NVPs by their customers (19), yet nearly all of the pharmacy staff felt uninformed about these 350 
products and were unsure how to handle customer enquiries amidst the scientific uncertainty 351 
and lack of guidance from peak professional bodies. Thus, pharmacists need to be provided 352 
with education/training and relevant resources so that they can provide unbiased and evidence-353 
based advice for customers. 354 
Our study has a number of methodological limitations and caveats that should be taken into 355 
account while interpreting the results. First, the questionnaire used for assessing the perception 356 
of respondents was not validated. As this study employed a descriptive cross-sectional study 357 
design and recruited a convenience sample of individuals attending urban pharmacies in 358 
Brisbane, the results may not be generalizable to the wider population. Moreover, this study 359 
should be regarded as a snapshot in time as the science surrounding NVPs is fast moving and 360 
beliefs of respondents may have changed since data collection, although the regulatory 361 
framework in Australia has remained unchanged since the study was conducted. Nonetheless, 362 
this survey provides valuable insight into the existing gap in public perception of relative harm 363 
of nicotine-containing products and informs the development of educational material for 364 
pharmacy staff to facilitate provision of evidence-based information to their customers. 365 
Conclusions 366 
Although pharmacy customers did not believe NVPs to be more harmful than combustible 367 
cigarettes, many respondents (particularly non-users) perceived nicotine-containing NVPs to 368 
be as harmful as combustible cigarettes. Misperceptions about relative risk of various nicotine-369 
containing products were also reflected in respondent regulatory recommendations as they 370 
tended to prefer a more restrictive regulatory approach if NVPs contain nicotine, supporting a 371 
complete ban or regulation as a medicinal product that requires a medical professional to 372 
control access. As tobacco smoking is associated with compromised health status, often 373 
requiring medical intervention, community pharmacies are an ideal setting for educating 374 
smokers about less harmful alternatives such as NVPs. The development of practice guidelines 375 
for pharmacy staff will ultimately assist in providing a customised, evidence-based and 376 
unbiased information to their customers. 377 
 378 
 379 
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